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Diabetes Susceptibility Observed in Genome-Wide
Association Data
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Willem H. Ouwehand,6,7 David P. Strachan,8 N. William Rayner,1,3 Mark Walker,9 Graham A. Hitman,10
Alex S.F. Doney,11 Colin N.A. Palmer,12 Andrew D. Morris,11 Andrew T. Hattersley,4,5
Eleftheria Zeggini,1 Timothy M. Frayling,4,5 and Mark I. McCarthy1,3
OBJECTIVE—This study examined how differences in the BMI
distribution of type 2 diabetic case subjects affected genome-
wide patterns of type 2 diabetes association and considered the
implications for the etiological heterogeneity of type 2 diabetes.
RESEARCH DESIGN AND METHODS—We reanalyzed data
from the Wellcome Trust Case Control Consortium genome-wide
association scan (1,924 case subjects, 2,938 control subjects:
393,453 single-nucleotide polymorphisms [SNPs]) after stratify-
ing case subjects (into “obese” and “nonobese”) according to
median BMI (30.2 kg/m2). Replication of signals in which alter-
native case-ascertainment strategies generated marked effect
size heterogeneity in type 2 diabetes association signal was
sought in additional samples.
RESULTS—In the “obese-type 2 diabetes” scan, FTO variants
had the strongest type 2 diabetes effect (rs8050136: relative risk
[RR] 1.49 [95% CI 1.34–1.66], P  1.3  1013), with only weak
evidence for TCF7L2 (rs7901695 RR 1.21 [1.09–1.35], P  0.001).
This situation was reversed in the “nonobese” scan, with FTO
association undetectable (RR 1.07 [0.97–1.19], P  0.19) and
TCF7L2 predominant (RR 1.53 [1.37–1.71], P  1.3  1014).
These patterns, confirmed by replication, generated strong com-
bined evidence for between-stratum effect size heterogeneity
(FTO: PDIFF  1.4  10
7; TCF7L2: PDIFF  4.0  10
6). Other
signals displaying evidence of effect size heterogeneity in the
genome-wide analyses (on chromosomes 3, 12, 15, and 18) did
not replicate. Analysis of the current list of type 2 diabetes
susceptibility variants revealed nominal evidence for effect size
heterogeneity for the SLC30A8 locus alone (RRobese 1.08 [1.01–
1.15]; RRnonobese 1.18 [1.10–1.27]: PDIFF  0.04).
CONCLUSIONS—This study demonstrates the impact of differ-
ences in case ascertainment on the power to detect and replicate
genetic associations in genome-wide association studies. These
data reinforce the notion that there is substantial etiological
heterogeneity within type 2 diabetes. Diabetes 58:505–510,
2009
Over the past year, the capacity to performlarge-scale high-density genome-wide associa-tion (GWA) analyses has provided the firstglobal view of the genetic etiology of type 2
diabetes, albeit one limited to the kinds of variants (com-
mon, modest-to-large effect sizes, tagged by single-
nucleotide polymorphisms (SNPs) on commercial array
platforms) for which such studies are powered (1–8).
These efforts have identified several novel diabetes sus-
ceptibility pathways, but also provide an opportunity to
explore, in systematic fashion, questions about the etio-
logical heterogeneity of type 2 diabetes.
One key question relates to the extent to which type 2
diabetes reflects a single monolithic condition, as opposed
to a set of distinct etiologies with common phenotypic
features. If the latter, the ability to identify disease sub-
types differing with respect to etiology, prognosis, progres-
sion, and treatment response may enable improved
clinical management. Indeed, a molecular classification of
diabetes subtype is already a reality for low-frequency
high-penetrance DNA variants responsible for monogenic
and syndromic forms of diabetes, such as maturity-onset
diabetes of the young and mitochondrial diabetes (9).
These are now considered etiologically distinct from mul-
tifactorial type 2 diabetes and benefit from specific clinical
and therapeutic approaches tailored to the particular
molecular diagnosis (9).
One striking feature of early GWA studies for type 2
diabetes was the observation that replicated associations
between variants in the FTO gene and type 2 diabetes
predisposition were mostly restricted to one study (1,7,8).
The failure of other scans (2,4–6), despite reasonable
power, to detect a diabetes association signal at FTO
became explicable once it was revealed that the primary
effect of FTO on diabetes risk was mediated through
adiposity (8). Most of the other GWA scans had, by design
or circumstance, preferentially ascertained lean type 2
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diabetic case subjects (2,4–6), thereby reducing the mag-
nitude of the case-control difference in adiposity and
attenuating the FTO association signal with respect to
diabetes.
These observations demonstrated that differences in
sample ascertainment could influence the ability to
detect individual signals and the landscape of suscepti-
bility variants detected by any given GWA study. Given
the key role played by replication in the evaluation of
the association signals emerging from such studies, an
appreciation of the genome-wide consequences of alter-
native case-ascertainment strategies is essential if ap-
propriate inferences are to be made, particularly where
there is evidence of substantial heterogeneity in effect
size estimates between studies.
We designed the present study to address two questions.
First, how might differences in type 2 diabetes case
ascertainment, according to BMI, affect the patterns of
association detected through GWA studies? Second, what
do such differences tell us about the etiological heteroge-
neity of type 2 diabetes?
To answer these questions, we used GWA data (393,453
SNPs, minor allele frequency 1%; see the supplementary
information in an online appendix at http://dx.doi.org/10.
2337/db08–0906) from the type 2 diabetes arm of the
Wellcome Trust Case Control Consortium (WTCCC) (1,7).
Because our main aim was to evaluate the impact of
alternate strategies for case ascertainment, we first di-
vided the type 2 diabetes case subjects into two strata of
equal size (“nonobese” type 2 diabetes and “obese” type 2
diabetes) using the median case BMI (30.2 kg/m2). We
then performed a GWA analysis (using similar proce-
dures as reported for the original scan [1,7]) comparing
each case stratum against the full set of 2,938 control
subjects (see supplementary information and Supple-
mentary Figure S1).
The results from this BMI-stratified reanalysis of
WTCCC type 2 diabetes GWA data (1,7) are displayed in
Fig. 1. As anticipated, given the known effects of FTO, the
association between FTO variants (e.g., rs8050136) and
type 2 diabetes was detectable only in the “obese type 2
diabetes” scan (RRobeseT2D 1.49 [1.34–1.66], RRnonobeseT2D
1.07 [0.97–1.19], between-stratum heterogeneity, by multi-
nomial logistic regression, PDIFF  7.5  10
7). In the
“obese type 2 diabetes” scan, FTO variants ranked first to
tenth in terms of effect size and association P value,
whereas in the “nonobese type 2 diabetes” scan, the
strongest association (rs8050136) ranked only 80,215th
(Table 1).
To confirm these findings, we used genotypes from
previously described type 2 diabetes case-control replica-
tion sample (RS) sets also of U.K. origin (1) (supplemen-
tary information). Analysis of FTO genotypes in these
samples using the same BMI stratification procedure (see
supplementary information) replicated the GWA results.
In the follow-up studies alone, conducted in the RSA and
RSB samples, rs8050136 generated values of (RRobeseT2D)
1.22 (1.13–1.32) and (RRnonobeseT2D) 1.05 (0.97–1.15) (PDIFF
0.004). When GWA and RS data were combined, the RR
estimates for the “obese” and “nonobese” scans were 1.30
(1.23–1.39) and 1.06 (1.00–1.14), respectively (PDIFF 
1.4  107) (Table 2).
SNPs in TCF7L2 exhibited the reverse pattern, with
variants ranked first to twelfth in the “nonobese” scan
(rs7901695: RRnonobeseT2D  1.53 [1.37–1.71]), but reaching
only 385th in the “obese” scan (rs7901695: RRobeseT2D 
1.21 [1.09–1.35], PDIFF  0.0005) (Table 1). This pattern
was reproduced in the replication samples (RSA and RSB,
rs7903146: RRnonobeseT2D 1.48 [1.36–1.62], RRobeseT2D 1.28
[1.18–1.39], PDIFF  0.002). Between-strata heterogeneity
was confirmed (PDIFF  4.0  10
6) in the GWA-RS
meta-analysis based on rs7903146 imputation (supplemen-
tary information and Table 2).
Inspection of GWA plots (Fig. 1) and reference to
overall type 2 diabetes association effect in the WTCCC
GWA analysis highlighted two other regions associated
with type 2 diabetes in the overall analysis, which dis-
played some evidence of between-stratum heterogeneity
(PDIFF  0.05) of effect size (Table 1). Variant rs7132840
(chromosome 12) displayed a pattern similar to TCF7L2
(i.e., predominant association in the “nonobese” scan), but
the overall picture of association and heterogeneity was
not confirmed within the replication samples (Supplemen-
tary Table S1). Furthermore, this SNP was not associated
with type 2 diabetes in the Diabetes Genetics Initiative
(DGI) and Finland–United States Investigation of NIDDM
Genetics (FUSION) GWA scans, both of which featured
predominantly nonobese case subjects (4,5). This SNP lies
250 kb from a variant (rs7961581) close to the tet-
raspanin 8 (TSPAN8) gene, which has recently been
shown, in a large-scale meta-analysis, to be associated
with type 2 diabetes (3). However, rs7132840 and
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FIG. 1. Genome-wide association results for the “obese” and “nono-
bese” type 2 diabetes scans. A: Genome-wide type 2 diabetes associa-
tion results for nonobese scan sample design. B: Genome-wide type 2
diabetes association results for obese scan sample design. The four loci
labeled were those associated with type 2 diabetes in the overall scan
for which stratification effects appeared most marked. (Please see
http://dx.doi.org/10.2337/db08-0906 for a high-quality digital represen-
tation of this figure.)
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rs7961581 are only in weak linkage disequilibrium (r2 
0.2), and rs7961581 shows no between-stratum heteroge-
neity of effect size (Table 3).
The other signal of interest (rs901130: chromosome 15)
evokes a pattern similar to that of FTO (Table 1). Unlike
FTO, this variant shows no evidence (P 0.4) of a primary
association with BMI, based on data from a large-scale
(n  16,876) GWA meta-analysis (10). In addition, there
was no effect-size heterogeneity detectable in the replica-
tion samples (RSA PDIFF  0.7, RSB not typed, Supplemen-
tary Table S1).
Next, we conducted an exploratory genome-wide anal-
ysis designed to detect additional variants that showed
evidence of novel type 2 diabetes association signals only
after BMI stratification (see supplementary information).
Two loci demonstrated both appreciable between-stratum
heterogeneity in type 2 diabetes association signal
(Breslow-Day P  1  103) and a within-stratum type 2
diabetes association (P  1  103 in either the “obese”
or “nonobese” case-control analysis) (Supplementary
Figure S2).
A locus on chromosome 3 defined by the SNPs
rs16827446 and rs1497313 (mutual r2 0.2) showed a pre-
dominant association in the “obese” scan (Supplementary
Table S2). Although these variants showed modest asso-
ciations with BMI in WTCCC case subjects (P  0.004 and
0.003, respectively), these relationships were not con-
firmed in the control subjects (P  0.5 and 0.1), nor in the
large-scale BMI meta-analysis previously mentioned (P 
0.2) (10) and the effect was not replicated in the RSA
sample (Supplementary Table S1).
The second locus (rs917836, chromosome 18) showed
evidence for a type 2 diabetes association only in the
“nonobese” type 2 diabetes scan (Supplementary Table
S2). However, as with rs7132840, this signal showed no
evidence of a replicated type 2 diabetes association in DGI
or FUSION scans, either separately (4,5) or in the recently
reported meta-analysis (3), and there was no replication
within RSA (Supplementary Table S1).
Finally, we considered BMI-stratified analyses performed
on 16 other confirmed type 2 diabetes susceptibility variants
derived from GWA analyses, classical candidate gene stud-
ies (KCNJ11, PPARG), and pathway-based analyses
(HNF1B, WFS1) (11–14) (Table 3, Supplementary Table
S3). For five of these signals (the primary signal near
CDKN2A/B plus those in CDKAL1, HHEX, NOTCH2, and
SLC30A8), there was some evidence that the association
signal was more marked in nonobese case subjects, but
this effect was only nominally significant for rs13266634 in
SLC30A8 (PDIFF  0.04). As with rs7903146 in TCF7L2,
this SLC30A8 SNP shows evidence for an association
between the risk allele and reduced BMI, which is re-
stricted to case subjects (Supplementary Table S4).
These findings emphasize the impact that case ascer-
tainment can have on the lead results obtained during a
GWA study. The findings we report at FTO are in line with
the expectation that variants in this gene exert their effect
on type 2 diabetes susceptibility through a primary effect
on adiposity. The “nonobese” scan we report here effec-
tively matches case subjects and control subjects for BMI
and, as with the DGI and French-Canadian scans (5,6), this
renders FTO invisible to detection as a type 2 diabetes
susceptibility locus.
Our findings for TCF7L2 are also confirmatory, since
the predominant action of TCF7L2 is known to involve a
deleterious effect on -cell function (15). This results in a
preferential association with nonobese type 2 diabetes,
which likely reflects a combination of direct physiological
effects (relative insulin deficiency) and ascertainment bias
(most genetic studies favor relatively early-onset case
subjects and may therefore oversample TCF7L2 risk ge-
notype case subjects who, because of marked -cell
deficiency, have become diabetic earlier and at lower
levels of BMI than those with no TCF7L2 risk genotypes).
Associations between TCF7L2 genotype and BMI in case
subjects have been observed in several previous studies
(16,17): our case data provide further evidence of these
effects, while also confirming that no BMI association is
evident in control subjects (Supplementary Table S4).
Apart from these regions, we found no clear examples
of loci where differences in case ascertainment led to
replicable effect size heterogeneity of sufficient magnitude
to have masked a strong type 2 diabetes association that
would have been detectable under the alternate case
ascertainment strategy. However, this does not necessarily
imply that FTO and TCF7L2 are the only loci for which
such heterogeneity of effect size could be important.
Indeed, for several other now-proven type 2 diabetes
TABLE 1
Selected stratified type 2 diabetes association results for the WTCCC GWA
Overall type 2
diabetes
association
(n  1,924/2,938) Passoc
Obese type 2
diabetes versus
control subjects
(n  958/2,938) Passoc
Nonobese type
2 diabetes
versus control
subjects
(n  955/2,938) Passoc PDIFF
FTO (rs8050136) 1.27 (1.17–1.38) 2.2 108 1.49 (1.34–1.66) 1.3 1013 1.07 (0.97–1.19) 0.19 7.5 107
FTO (rs9939609) 1.26 (1.16–1.37) 5.6 108 1.48 (1.33–1.64) 3.7 1013 1.07 (0.96–1.19) 0.24 7.7 107
TCF7L2 (rs7901695) 1.37 (1.26–1.49) 8.3 1013 1.21 (1.09–1.35) 0.001 1.53 (1.37–1.71) 1.2 1014 0.0005
TCF7L2* (rs7903146) 1.43 (1.31–1.56) 4.2 1015 1.38 (1.23–1.54) 1.4 108 1.48 (1.33–1.66) 4.4 1012 0.3
CHR15† (rs901130) 1.14 (1.06–1.22) 0.001 1.25 (1.16–1.34) 2.0 106 1.03 (0.91–1.13) 0.6 0.0004
CHR12 (rs7132840) 1.20 (1.11–1.31) 2.2 108 1.09 (0.98–1.21) 0.096 1.32 (1.19–1.46) 2.1 107 0.004
The loci shown in this table included those with some evidence of type 2 diabetes association in the overall analysis (P  0.001) for which
there was also evidence of effect size heterogeneity (Fig. 1). Median BMI  30.2 kg/m2, n  number of case subjects/control subjects. RR
estimates overall and by strata are generated from multinomial logistic regression. Passoc represents P value for basic type 2 diabetes
association result; PDIFF represents a test for the difference in estimates derived from strata. *rs7903146 imputed in the GWA data as not
directly typed on the Affymetrix 500-k chip. †Data presented per copy of the major allele (as opposed to minor for others).
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susceptibility signals, we found modest differences in
effect size, consistent with the evidence that (like
TCF7L2) their type 2 diabetes predisposition effect is
mediated through reduced -cell function (2,18–21). The
fact that significant heterogeneity of effect size could not
be detected in our analysis is most likely a reflection of
power, since the modest overall effect sizes place an upper
bound on the extent of between-stratum heterogeneity
that could be detected in our analysis. Further work is
needed to consider the effect of BMI on effect size het-
erogeneity in the larger type 2 diabetes GWA datasets now
being generated through meta-analysis.
What are the key messages from this analysis? First,
differences in case ascertainment (in this study based on
BMI) can have a dramatic effect on the ranking of signals
obtained from GWA scans. This can sometimes mean that
even genuine signals with substantial effect sizes (such as
FTO) fail the test of replication in additional samples
(1,2,4–8). While adiposity represents one of the more
obvious criteria that could be used to define case-selection
strategies, it is plausible that other differences in ascer-
tainment scheme (for example, with respect to age of
onset or family history) could also generate appreciable
effect size heterogeneity. Even modest differences in effect
size (too small to be easily detected in the kinds of
analyses we have performed) could have a substantial
impact on the power to detect signals by replication.
Second, awareness of the potential for effect size heter-
ogeneity consequent on case ascertainment strategies can
not only “rescue” genuine associations that might other-
wise have been dismissed because of apparent failure to
replicate, but also provides insight into the mechanisms
through which the associated variants act. This phenome-
non, which we have termed “informative heterogeneity,”
requires, of course, that the factor explaining the hetero-
geneity can be identified. In the case of FTO, the observa-
tion that effect size heterogeneity reflected differences in
case-control matching for BMI provided the clue that these
variants had a primary effect on adiposity (8).
Third, these studies provide a genetic counterpart to the
expectation from physiological first principles that defects
in -cell function would predominate in the pathogenesis
of “nonobese” as opposed to “obese” type 2 diabetes. On
their own, our findings do not provide justification for
TABLE 2
BMI-stratified analyses for FTO and TCF7L2 loci in replication samples
Obese type 2 diabetes vs. control subjects
RSA (n  1,718/3,596) RSB (n  362 /1,750) RSA  RSB WTCCC  RS Passoc
FTO (rs8050136) 1.20 (1.10–1.30) 1.29 (1.09–1.53) 1.22 (1.13–1.32) 1.30 (1.23–1.39) 1.7 1017
TCF7L2 (WTCCC imputed) 1.24 (1.13–1.36) 1.44 (1.20–1.72) 1.28 (1.18–1.39) 1.31 (1.23–1.40) 6.1 1016
TCF7L2 (WTCCC naive) 1.24 (1.13–1.36) 1.44 (1.20–1.72) 1.28 (1.18–1.39) 1.25 (1.17–1.34) 1.3 1011
Stratification in the RS samples is based on the case median BMI from the WTCCC (30.2 kg/m2). Numbers in column headers refer to number
of case and control subjects. RR estimates by strata are generated from multinomial logistic regression. For meanings of “imputed” and
“naive” analyses, see the supplementary information. Passoc represents the P value for type 2 diabetes association derived from meta-analysis
including WTCCC data; PDIFF represents a test for between-strata heterogeneity.
TABLE 3
BMI-stratified analyses for other confirmed type 2 diabetes susceptibility loci in GWA and RS samples
Obese type 2 diabetes vs. control subjects
Obese type 2
diabetes
Obese type 2
diabetes RSA  RSB WTCCC  RS Passoc
RSA (n  1,718 /3,596) RSB (n  362 /1,750)
rs10811661 (CDKN2B) 1.17 (1.04–1.31) 0.98 (0.79–1.22) 1.12 (1.01–1.24) 1.13 (1.05–1.24) 0.002
rs10946398 (CDKAL) 1.12 (1.03, 1.23) 1.18 (1.00, 1.40) 1.13 (1.05–1.23) 1.14 (1.07–1.21) 0.00004
rs5015480* (HHEX) 1.01 (0.93–1.10) 1.15 (0.97–1.35) 1.04 (0.96–1.12) 1.10 (1.03–1.17) 0.003
rs13266634† (SLC30A8) 1.08 (0.99–1.18) 1.15 (1.00–1.39) 1.10 (1.01–1.19) 1.08 (1.01–1.15) 0.03
rs4402960 (IGF2BP2) 1.10 (1.00–1.20) 0.98 (0.82–1.17) 1.07 (0.99–1.16) 1.12 (1.05–1.19) 0.0008
rs564398 (CDKN2B) 1.17 (1.07–1.28) 1.03 (0.87–1.22) 1.14 (1.05–1.22) 1.15 (1.08–1.22) 0.00001
rs2934381 (NOTCH2) 1.08 (0.94–1.23) 0.99 (0.76–1.28) 1.06 (0.944–1.19) 1.08 (0.98–1.18) 0.1
rs7578597‡ (THADA) 1.07 (0.93–1.24) 1.23 (0.93–1.62) 1.11 (0.97–1.26) 1.14 (1.27–1.02) 0.02
rs4607103 (ADAMTS9) 1.04 (0.94–1.15) 1.13 (0.93–1.37) 1.06 (0.97–1.16) 1.10 (1.02–1.18) 0.02
rs864745 (JAZF1) 1.04 (0.96–1.13) 1.40 (1.18–1.65) 1.10 (1.02–1.19) 1.12 (1.05–1.19) 0.0003
rs12779790‡ (CDC123/CAMK1D) 1.11 (0.99–1.23) 1.29 (1.05–1.58) 1.14 (1.04–1.25) 1.15 (1.06–1.24) 0.0005
rs7961581 (TSPAN/LGR5) 1.12 (1.02–1.23) 0.99 (0.83–1.18) 1.09 (1.00–1.18) 1.13 (1.06–1.21) 0.0002
rs757210 (HNF1B) 1.03 (0.95–1.13) 1.02 (0.86–1.21) 1.03 (0.96–1.11) 1.04 (0.97–1.11) 0.3
rs10010131 (WFS1) 1.04 (0.96–1.12) 1.05 (0.88–1.20) 1.04 (0.97–1.11) 1.05 (0.99–1.11) 0.1
rs1801282 (PPARG) 1.15 (1.03–1.25) 1.43 (1.04–1.66) 1.17 (1.06–1.26) 1.19 (1.10–1.26) 0.00004
rs5219 (KCNJ11) 1.21 (1.11–1.32) 1.02 (0.86–1.22) 1.25 (1.15–1.36) 1.19 (1.11–1.27) 5.2 107
Stratification in the RS samples is based on the case median BMI from the WTCCC (30.2 kg/m2). Numbers in column headers refer to number
of case subjects and control subjects overall. RR estimates by strata are generated from multinomial logistic regression. Passoc represents P
value for type 2 diabetes association derived from meta-analysis including WTCCC data; PDIFF represents a test for between-strata
heterogeneity. *Meta-analysis only based on rs5015480 and the perfect proxy rs1111875 in RSA and RSB. †rs13266634 (SLC30A8) was not well
captured by the Affymetrix chip, so WTCCC data are derived from bespoke genotyping. ‡Imputed genotype data. The CDKN2B locus is
represented by two SNPs given evidence of two independent signals in this region (1). Detailed WTCCC results are presented in
Supplementary Table S2.
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considering these as distinct phenotypes, as opposed to
extremes on an etiological continuum. However, our find-
ings do suggest that, as additional variants affecting type 2
diabetes susceptibility are defined, genetic data could
complement physiological studies in defining patient sub-
groups that differ substantially from a pathogenetic
perspective and may therefore benefit from different pre-
ventative and therapeutic approaches.
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TABLE 2
Continued
Nonobese type 2 diabetes vs. control subjects
RSA (n  1,407/3,596) RSB (n  270 /1,750) RSA  RSB WTCCC  RS Passoc Pdiff
1.06 (1.96–1.16) 1.07 (0.88–1.29) 1.05 (0.97–1.15) 1.06 (1.00–1.14) 0.06 1.4 107
1.50 (1.36–1.65) 1.45 (1.19–1.77) 1.48 (1.36–1.62) 1.49 (1.39–1.59) 9.1 1030 0.002
1.50 (1.36–1.65) 1.45 (1.19–1.77) 1.48 (1.36–1.62) 1.51 (1.41–1.61) 2.9 1032 4.0  106
TABLE 3
Continued
Nonobese type 2 diabetes vs. control subjects
Nonobese type 2
diabetes
Nonobese type 2
diabetes RSA  RSB WTCCC  RS Passoc Pdiff
RSA (n  1,407 /3,596) RSB (n  270/1,750)
1.25 (1.10–1.42) 1.28 (0.97–1.68) 1.25 (1.12–1.41) 1.26 (1.15–1.38) 7.0 107 0.09
1.11 (1.01–1.22) 1.29 (1.06–1.56) 1.14 (1.05–1.24) 1.18 (1.11–1.26) 7.2 107 0.4
1.10 (1.01–1.21) 1.21 (1.00–1.46) 1.13 (1.03–1.22) 1.16 (1.08–1.24) 0.00002 0.2
1.16 (1.06–1.28) 1.19 (0.96–1.47) 1.17 (1.07–1.28) 1.18 (1.10–1.27) 7.1 106 0.04
1.10 (1.00–1.21) 1.12 (0.92–1.36) 1.11 (1.01–1.20) 1.10 (1.03–1.18) 0.005 0.7
1.10 (1.00–1.21) 1.07 (0.89–1.29) 1.09 (1.01–1.19) 1.12 (1.05–1.20) 0.0006 0.5
1.14 (1.00–1.31) 1.05 (0.78–1.40) 1.12 (0.99–1.27) 1.12 (1.02–1.23) 0.02 0.5
1.12 (0.96–1.31) 1.13 (0.83–1.54) 1.12 (1.05–1.20) 1.13 (1.06–1.20) 0.0002 0.5
1.06 (0.96–1.18) 1.05 (0.85–1.31) 1.01 (0.96–1.17) 1.09 (1.01–1.17) 0.04 0.9
1.02 (0.93–1.12) 1.03 (0.85–1.24) 1.02 (0.94–1.11) 1.08 (1.01–1.15) 0.02 0.6
1.10 (0.99–1.24) 1.20 (0.95–1.51) 1.12 (1.01–1.24) 1.14 (1.05–1.23) 0.002 0.9
1.06 (0.96–1.17) 1.16 (0.95–1.41) 1.07 (0.99–1.16) 1.13 (1.06–1.20) 0.0003 0.9
1.05 (0.96–1.15) 1.13 (0.94–1.37) 1.07 (0.98–1.16) 1.07 (1.00–1.15) 0.06 0.5
1.12 (1.04–1.20) 1.14 (0.96–1.29) 1.12 (1.05–1.19) 1.13 (1.06–1.18) 0.0001 0.05
1.10 (0.97–1.21) 1.19 (0.62–1.53) 1.11 (0.98–1.21) 1.13 (1.04–1.22) 0.006 0.3
1.20 (1.10–1.32) 1.11 (0.91–1.36) 1.23 (1.13–1.35) 1.25 (1.16–1.34) 1.3 109 0.2
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